Acetic acid- and phenyl-p-benzoquinone-induced overt pain-like behavior depends on spinal activation of MAP kinases, PI3K and microglia in mice  by Pavao-de-Souza, Gabriela F. et al.
Pharmacology, Biochemistry and Behavior 101 (2012) 320–328
Contents lists available at SciVerse ScienceDirect
Pharmacology, Biochemistry and Behavior
j ourna l homepage: www.e lsev ie r .com/ locate /pharmbiochembehAcetic acid- and phenyl-p-benzoquinone-induced overt pain-like behavior depends
on spinal activation of MAP kinases, PI3K and microglia in mice
Gabriela F. Pavao-de-Souza a,1, Ana C. Zarpelon a,1, Giovana C. Tedeschi a,1, Sandra S. Mizokami a,
Joice S. Sanson b, Thiago M. Cunha c, Sérgio H. Ferreira c, Fernando Q. Cunha c,
Rubia Casagrande b, Waldiceu A. Verri Jr. a,⁎
a Departamento de Patologia, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Rod. Celso Garcia Cid KM480 PR445, CEP 86051-990, Cx Postal 6001, Londrina,
Paraná, Brazil
b Department of Pharmaceutical Sciences, Healthy Science Centre, Londrina State University, Av. Robert Koch, 60, CEP 86038-350 Londrina, Parana, Brazil
c Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Sao Paulo, Avenida Bandeirantes, 3900, CEP 14049-900, Ribeirao Preto, Sao Paulo, Brazil⁎ Corresponding author at: Departamento de Patolo
Londrina, Rod. Celso Garcia Cid KM480 PR445, CEP 86
drina, Paraná, Brazil. Tel.: +55 43 3371 4979; fax: +55
E-mail addresses: waverri@uel.br, waldiceujr@yahoo
1 G.F.P.S., G.C.T. and A.C.Z. contributed equally to this
0091-3057 © 2012 Elsevier Inc.
doi:10.1016/j.pbb.2012.01.018
Open access under the Elsea b s t r a c ta r t i c l e i n f oArticle history:
Received 25 April 2011
Received in revised form 30 November 2011
Accepted 22 January 2012
Available online 28 January 2012
Keywords:
ERK
JNK
p38
PI3K
Microglia
Pain
Formalin
Abdominal contortions
Acetic acid
Phenyl-p-benzoquinone
Inﬂammation
Visceral painThe acetic acid and phenyl-p-benzoquinone are easy and fast screening models to access the activity of novel
candidates as analgesic drugs and their mechanisms. These models induce a characteristic and quantiﬁable
overt pain-like behavior described as writhing response or abdominal contortions. The knowledge of the
mechanisms involved in the chosen model is a crucial step forward demonstrating the mechanisms that
the candidate drug would inhibit because the mechanisms triggered in that model will be addressed. Herein,
it was investigated the role of spinal mitogen-activated protein (MAP) kinases ERK (extracellular signal-
regulated kinase), JNK (Jun N-terminal Kinase) and p38, PI3K (phosphatidylinositol 3-kinase) and microglia
in the writhing response induced by acetic acid and phenyl-p-benzoquinone, and ﬂinch induced by formalin
in mice. Acetic acid and phenyl-p-benzoquinone induced signiﬁcant writhing response over 20 min. The no-
ciceptive response in these models were signiﬁcantly and in a dose-dependent manner reduced by intrathe-
cal pre-treatment with ERK (PD98059), JNK (SB600125), p38 (SB202190) or PI3K (wortmannin) inhibitors.
Furthermore, the co-treatment with MAP kinase and PI3K inhibitors, at doses that were ineffective as single
treatment, signiﬁcantly inhibited acetic acid- and phenyl-p-benzoquinone-induced nociception. The treat-
ment with microglia inhibitors minocycline and ﬂuorocitrate also diminished the nociceptive response. Sim-
ilar results were obtained in the formalin test. Concluding, MAP kinases and PI3K are important spinal
signaling kinases in acetic acid and phenyl-p-benzoquinone models of overt pain-like behavior and there is
also activation of spinal microglia indicating that it is also important to determine whether drugs tested in
these models also modulate such spinal mechanisms.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
The animal models evaluate two main symptoms of pain: i)
hyperalgesia and allodynia or ii) overt nociception/overt pain-like be-
havior. Hyperalgesia is deﬁned as an increase of pain sensation
caused by a stimulus that normally induces pain and allodynia as
pain due to a stimulus that does not normally provoke pain. Both re-
sult from the sensitization of nociceptors in which, for instance, in-
ﬂammatory mediators activate second messenger pathways such as
cyclic AMP, protein kinase A and protein kinase C with subsequent
phosphorylation of the voltage-dependent sodium channels and thegia, Universidade Estadual de
051-990, Cx Postal 6001, Lon-
43 3371 4387.
.com.br (W.A. Verri).
study.
vier OA license.inhibition of the voltage-dependent potassium channels resulting in
the lowering of the nociceptor threshold and increasing neuronal
membrane excitability (Verri et al., 2006). Hyperalgesia can be eli-
cited in sensitized tissues by mechanical (Ferreira et al., 1978; Verri
et al., 2008a) and thermal (Hargreaves et al., 1988) stimuli.
In overt nociception/overt pain-like behavior, an inﬂammatory
stimulus induces a declared behavior such as paw ﬂinch or licking
and abdominal contortions (writhing) without further mechanical
or thermal external stimuli. This declared behavior occurs because
the overt nociceptive stimuli activate or induce fast production of en-
dogenousmediators that activate the nociceptors. These stimuli are in
general chemical (phenyl-p-benzoquinone—PBQ, acetic acid, forma-
lin) but may also be biological (zymosan) (Collier et al., 1968;
Dubuisson and Dennis, 1977; Verri et al., 2006, 2008b).
The writhing response induced by PBQ and acetic acid are widely
used models because they are easy to learn, replicable, fast to per-
form, and there is no need of special equipments (Verri et al., 2006).
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TNFα (tumor necrosis factor α), IL (Interleukin)-1β and chemokines
act in synergy to induce the writhing response. These cytokines act
in synergy since the injection of a pool of cytokines (TNFα, IL-1β
and chemokine) rather than the injection of an isolated cytokine in-
duces writhing response while inhibiting one of these cytokines di-
minishes the acetic acid-induced writhing response. However, the
magnitude/number of writhing induced by injecting a pool of cyto-
kines (TNFα, IL-1β and CXCL1 chemokine) is much lower compared
to that induced in the acetic acid (Ribeiro et al., 2000) suggesting
the participation of other nociceptive pathways. In fact, cyclooxigen-
ase products (Ballou et al., 2000) and cysteinyl leukotrienes (Jain et
al., 2001) also contribute to nociception in this model. The writhing
response in the acetic acid model is reduced by treatment with
opiods, cyclooxigenase inhibitors, and a variety of natural products
(Valerio et al., 2007; Verri et al., 2008b). The PBQ model presents a
similar pharmacological proﬁle although there are some differences
in the mechanisms. For instance, the PBQ but not the acetic acid
writhing depends on cytokines such as IL-18 and interferon (IFN)-γ,
and endothelin-1 (Verri et al., 2008b). It remains to be determined
whether these peripheral mechanistic differences result in differ-
ences in spinal or supra spinal mechanisms.
Similar to the acetic acid model, there is also participation of
TNFα, IL-1β and CXCL1 in the second phase of the formalin test
(Chichorro et al., 2004). Nevertheless, there are some other important
mechanisms in the formalin test such as dorsal root ganglia activation
of the mitogen-activated protein (MAP) kinase ERK (extracellular
signal-regulated kinases) (Alter et al., 2010) and spinal activation of
PI3K (phosphatidylinositil 3-kinase) (Pezet et al., 2008). In fact, evi-
dence suggests spinal inhibition of pain processing as a successful
strategy to reduce pain with reduced incidence of systemic side effect
by targeting cellular activity (e.g. microglia, astrocytes and neurons),
kinases and other molecules. In addition to formalin test, spinal inhi-
bition of MAP kinases p38, JNK (Jun N-terminal Kinase) and ERK, and
PI3K attenuate carrageenin-induced peripheral hyperalgesia
(Svensson et al., 2003; Choi et al., 2010; Fitzsimmons et al., 2010), cy-
tokine (e.g. TNFα, G-CSF [granulocyte-colony stimulating factor])-in-
duced mechanical hyperalgesia (Carvalho et al., 2011; Zhang et al.,
2011), and nerve lesion-induced neuropathic pain (Obata et al.,
2004; Xu et al., 2007; Gao and Ji, 2010). Thus, consistent data support
that spinal inhibition of MAP kinases and PI3K reduce inﬂammatory
and neuropathic pain. Therefore, investigating whether a potential
analgesic drug presents inhibitory effects on spinal MAP kinases and
PI3K is an important approach to determine its mechanisms. In this
sense, the knowledge of the mechanisms involved in the nociception
model and deﬁning the nociception model is a crucial step of a study.
Cytokines such as TNFα and IL-1β mediate the writhing response
(Ribeiro et al., 2000) and induce spinal or neuronal activation of MAP
kinases and/or PI3K (Davis et al., 2006; Zhang et al., 2011). However,
it is not known whether acetic acid and PBQ induce overt pain-like
behavior via spinal activation of p38, ERK and JNK, and/or PI3K or
the participation of spinal microglia in writhing response. Therefore,
it was evaluated the spinal mechanisms involved in acetic acid- and
PBQ-induced writing response in mice focusing on the participation
of MAP kinases, PI3K and microglia. Two models of writhing response
were used to assess whether this response depends on similar spinal
mechanisms despite some peripheral mechanistic differences. Fur-
thermore, the formalin model was used for mechanistic comparison
purposes.
2. Material and methods
2.1. Animals
The experiments were performed on male Swiss mice (20–25 g,
Universidade Estadual de Londrina, Londrina, PR, Brazil) housed instandard clear plastic cages (six per cage) with free access to food
and water. All behavioral testing was performed between 9:00 am
and 5:00 pm in a temperature-controlled room. Animals' care and
handling procedures were in accordance with the International Asso-
ciation for Study of Pain (IASP) guidelines and with the approval of
the Ethics Committee of the Universidade Estadual de Londrina. All
efforts were made to minimize the number of animals used and
their suffering. It is noteworthy that different experimenters pre-
pared the solutions, made the administrations and performed the
evaluation of overt pain-like behavior.
2.2. Writhing response tests
The PBQ (Emele and Shanaman, 1967)- and acetic acid (Collier et
al., 1968)-induced writhing models were performed as previously de-
scribed at doses determined previously (Verri et al., 2008b; Valerio et
al., 2009). PBQ (diluted in DMSO 2%/saline; 1890 μg/kg), acetic acid
(0.8% v/v, saline, 10 ml/kg) or vehicle was injected into the peritoneal
cavities of mice. Each mouse was placed in a large glass cylinder and
the intensity of nociceptive behavior was quantiﬁed by counting the
total number of writhes (contraction of the abdominal muscle togeth-
er with a stretching of hind limbs or rotation of the trunk) occurring
between 0 and 20 min after stimulus injection. The intensity of the
writhing response was expressed as the cumulative number of writh-
ings at 2 min interval over 20 min or the total writhing over 20 min.
2.3. Formalin test
The number of paw ﬂinches was determined between 0 and
30 min after intraplantar injection of 25 μL of formalin 1.5% as previ-
ously described (Valerio et al., 2009). The period was divided in inter-
vals of 5 min and clearly demonstrated the presence of the ﬁrst and
second phases, which are characteristic of the method.
2.4. Intrathecal (i.t.) drug administration
The i.t. injections were performed under light halothane anesthesia
(1–2%). The dorsal fur of each mouse was shaved, the spinal column
was arched, and a 29-gauge needle was directly inserted into the sub-
arachnoid space, between the L4 and L5 vertebrae (Mestre et al., 1994).
Correct i.t. positioning of the needle tip was conﬁrmed by manifestation
of a characteristic tail ﬂick response. A 5 μl volume containing the test
agent (PD98059, SP600125, SB202190, wortmannin, minocycline or
ﬂuorocitrate) was slowly injected. Note that drugs delivered to the sub-
arachnoidal space by i.t. injection can diffuse into the cerebrospinal ﬂuid,
which bathes the spinal cord, the dorsal roots, and part of dorsal root
ganglion (Funez et al., 2008).
2.5. Drugs
Drugs were obtained from the following sources: acetic acid and
formalin from Mallinckrodt Baker, S.A (Mexico City, Mexico);
phenyl-p-benzoquinone, minocycline (50 μg/intrathecal [i.t.]), ﬂuoro-
citrate (1.6 μg/intrathecal [i.t.]), PD98059 (0.1–10 μg/intrathecal
[i.t.]), SB202190 (0.1–10 μg/i.t.), SP600125 (0.1–10 μg/i.t.), and wort-
mannin (0.1–10 μg/i.t.) were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Acetic acid and formalin were dissolved in saline (NaCl
0.9%), PBQ, minocycline and ﬂuorocitrate were dissolved in 2%
DMSO in saline, and all other compounds were dissolved in 20%
DMSO in saline.
2.6. Statistical analysis
Results are presented as means±s.e.m. of measurements made on
6 mice in each group. Two-way analysis of variance (ANOVA) was
used to compare the groups and doses at all times (curves). The
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teraction. When there was a signiﬁcant time versus treatment interac-
tion, one-way ANOVA followed by Bonferroni's t-test was performed
for each time. On the other hand, when the nociceptive responses
were presented as total writhing within 20 min or at indicated time
period, the differences between responses were evaluated by one-
way ANOVA followed by Bonferroni's t-test. Statistical differences
were considered to be signiﬁcant at Pb0.05.
3. Results
3.1. Role of spinal ERK activation in acetic acid-, PBQ- and
formalin-induced overt pain-like response
Mice were treated intrathecally (i.t.) with the MEK1/2 inhibitor
(prevents ERK1/2 activation) PD98059 (1–10 μg or 0.1–10 μg) or ve-
hicle (5 μl of 20% DMSO in saline) 30 min before intraperitoneal
(i.p.) acetic acid (Fig. 1A), PBQ (Fig. 1B) or intraplantar (i.pl.) formalin
(Fig. 1C) stimulus. These dose ranges and vehicle concentration were
chosen based on previous studies (Zhuang et al., 2004, 2005; Carvalho
et al., 2011). Acetic acid (Fig. 1A), PBQ (Fig. 1B) i.p. injection, and for-
malin (Fig. 1C) i.pl. injection induced signiﬁcant nociceptive behavior.
There was a tendency of dose-dependent reduction of acetic acid
(Fig. 1A), PBQ (Fig. 1B) and formalin (Fig. 1C) writhing response by
PD98059 treatment. The dose of 1 μg of PD98059 did not signiﬁcantly
inhibit the nociceptive response induced by acetic acid (Fig. 1A) or
PBQ (Fig. 1B). The dose of 3 μg of PD98059 reduced acetic acid-
induced writhing between 6 and 14 min (Fig. 1A), and PBQ-induced
writhing between 6 and 8 min (Fig. 1B). On the other hand, the
dose of 10 μg of PD98059 signiﬁcantly inhibited acetic acid-induced
writhing response between 6 and 20 min compared to vehicle
i.t.+acetic acid i.p. group (Fig. 1A). In the PBQ model, there was sig-
niﬁcant inhibition of nociceptive behavior by PD98059 10 μg treat-
ment between 6 and 20 min compared to vehicle i.t.+PBQ i.p.
group and between 18 and 20 min compared to the lower dose of
PD98059 tested (Fig. 1B). In the formalin model, the dose of 0.1 of
PD98059 did not signiﬁcantly inhibit the nociceptive response
(ﬂinches). On the other hand, the dose of 1 μg of PD98059 inhibited
the formalin-induced ﬂinches at 5 and 25 min, and the dose of 10 μgFig. 1. Role of spinal ERK in acetic acid-, phenyl-p-benzoquinone (PBQ) and formalin-indu
(1–10 μg or 0.1–10 μg/5 μL) or vehicle (20% DMSO in saline) 30 min before acetic acid (0
(1.5%, 25 μL) (Panel C) intraplantar (i.pl.) stimulus. The vehicle of acetic acid and formalin
were determined over 20 min and presented at 2 min interval for PBQ and acetic acid, and th
at 5 min interval. Results are presented as means±s.e.m. of 6 mice per group, and are repres
with acetic acid, PBQ and formalin; **Pb0.05 compared with lower dose of PD98059 (One-of PD98059 signiﬁcantly inhibited formalin-induced ﬂinch response
in all times evaluated (0–30 min) compared to vehicle i.t.+formalin
(i.pl.) and compared to the lower dose of PD98059 tested (Fig. 1C).
3.2. Role of spinal JNK in acetic acid-, PBQ- and formalin-induced
overt-pain like response
Mice were treated i.t. with the JNK inhibitor SP600125 (1–10 μg or
0.1–10 μg) or vehicle (5 μl of 20% DMSO in saline) 30 min before i.p.
acetic acid (Fig. 2A), PBQ (Fig. 2B) or formalin (Fig. 2C) stimulus.
These dose ranges and vehicle concentrationwere chosen based on pre-
vious studies (Doya et al., 2005; Carvalho et al., 2011). Acetic acid
(Fig. 2A), PBQ (Fig. 2B) and formalin (Fig. 2C) induced signiﬁcant noci-
ceptive behavior. There was a tendency of dose-dependent reduction
of acetic acid (Fig. 2A), PBQ (Fig. 2B) and formalin (Fig. 2C) writhing re-
sponse by SP600125 treatment. The doses of 1 and 3 μg of SP600125 did
not signiﬁcantly inhibit acetic acid-inducedwrithing response (Fig. 2A),
and the dose of 10 μg of SP600125 signiﬁcantly inhibited acetic acid-
induced writhing response between 10–20 min compared to vehicle
i.t.+acetic acid i.p. group, and at 20 min compared to the lower dose
of SP600125 (Fig. 2A). In the PBQ model, the doses of 1 and 3 μg of
SP600125 did not affect the nociceptive behavior, except that the dose
of 3 μg presented signiﬁcant inhibition at 12 min. There was signiﬁcant
inhibition of nociceptive behavior by SP600125 treatment between 6
and 20 min compared to vehicle i.t.+acetic acid i.p. group (Fig. 2B).
The dose of 0.1 μg of SP600125 did not signiﬁcantly inhibit formalin-
induced ﬂinch response (Fig. 2C), and the dose of 1 μg of SP600125 sig-
niﬁcantly inhibited formalin-induced ﬂinch response between 25 and
30 min compared to vehicle i.t.+formalin i.p. group. The dose of 10 μg
signiﬁcantly inhibited formalin-induced ﬂinch response in all times
evaluated compared with vehicle i.t.+formalin (paw) and compared
to the lower dose of SP600125 (Fig. 2C).
3.3. Role of spinal p38 in acetic acid-, PBQ- and formalin-induced overt
pain-like response
Mice were treated i.t. with the p38 inhibitor SB202190 (0.1–10 μg)
or vehicle (5 μl of 20% DMSO in saline) 30 min before acetic acid
(Fig. 3A), PBQ (Fig. 3B) or formalin (Fig. 3C) stimulus. These doseced overt pain-like behavior. Mice received intrathecal (i.t.) treatment with PD98059
.8%) (Panel A), PBQ (1890 μg/kg) (Panel B) intraperitoneal (i.p.) stimulus or formalin
was saline and PBQ 2% DMSO in saline. The cumulative number of writhing responses
e number of ﬂinches induced by formalin were determined over 30 min and presented
entative of 2 separated experiments. *Pb0.05 compared with saline; #Pb0.05 compared
way ANOVA followed by Bonferroni's test).
Fig. 2. Role of spinal JNK in acetic acid-, PBQ- and formalin-induced overt pain-like behavior. Mice received i.t. treatment with SP600125 (1–10 μg or 0.1–10 μg/5 μL) or vehicle (20%
DMSO in saline) 30 min before acetic acid (Panel A), PBQ (Panel B) i.p. stimulus and formalin (Panel C) i.pl. stimulus. The vehicle of acetic acid and formalin was saline and PBQ 2%
DMSO in saline. The cumulative number of writhing responses induced by acetic acid and PBQ were determined over 20 min and presented at 2 min interval, and the number of
ﬂinches induced by formalin were determined over 30 min and presented at 5 min interval. Results are presented as means±s.e.m. of 6 mice per group, and are representative of 2
separated experiments. *Pb0.05 compared with saline; #Pb0.05 compared with acetic acid, PBQ and formalin; **Pb0.05 compared with the lower dose of SP600125 (One-way
ANOVA followed by Bonferroni's test).
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studies (Chen et al., 2009; Carvalho et al., 2011). Acetic acid
(Fig. 3A), PBQ (Fig. 3B) and formalin (Fig. 3C) induced signiﬁcant no-
ciceptive behavior. There was a tendency of reduction with the doses
of 1 and 3 μg of SB202190, but it was not signiﬁcant in the acetic acid
model (Fig. 3A). On the other hand, the acetic acid-induced writhing
response was inhibited between 8 and 20 min by the dose of 10 μg of
SB202190 compared to vehicle i.t.+acetic acid i.p. group (Fig. 3A).
The PBQ-induced writhing response was not signiﬁcantly inhibited
by 1 μg of SB202190. The dose of 3 μg of SB202190 inhibited
PBQ-induced writhing response only at 20 min compared to vehi-
cle i.t.+PBQ i.p. group (Fig. 3B). Regarding the dose of 10 μg of
SB202190 in the PBQ model, it inhibited the writhing responseFig. 3. Role of spinal p38 in acetic acid-, PBQ- and formalin -induced overt pain-like behavior
DMSO in saline) 30 min before acetic acid (Panel A), PBQ (Panel B) i.p. stimulus and formali
DMSO in saline. The cumulative number of writhing responses induced by acetic acid and P
ﬂinches induced by formalin were determined over 30 min and presented at 5 min interval.
separated experiments. * Pb0.05 compared with saline; # Pb0.05 compared with the acetic
ANOVA followed by Bonferroni's test).between 6 and 20min, and at 14 min this inhibitionwas also signiﬁcant
compared to the lower dose of SB202190 tested (Fig. 3B). The dose of
0.1 and 1 μg of SB202190 did not signiﬁcantly inhibit formalin-
induced ﬂinch response (Fig. 3C). The dose of 10 μg signiﬁcantly inhib-
ited formalin-induced ﬂinch response in all times evaluated compared
with vehicle i.t.+formalin (paw) and compared to the lower dose of
SB202190 on times 5, 10, 15, 25, 30 min (Fig. 3C).
3.4. Role of spinal PI3K in acetic acid-, PBQ- and formalin-induced overt
pain-like behavior response
Mice were treated i.t. with the PI3K inhibitor wortmannin
(1–10 μg or 0.1–10 μg) or vehicle (5 μl of 20% DMSO in saline). Mice received i.t. treatment with SB202190 (1–10 μg or 0.1–10 μg/5 μL) or vehicle (20%
n (Panel C) i.pl. stimulus. The vehicle of acetic acid and formalin was saline and PBQ 2%
BQ were determined over 20 min and presented at 2 min interval, and the number of
Results are presented as means±s.e.m. of 6 mice per group, and are representative of 2
acid, PBQ, formalin; ** Pb0.05 compared with the lower dose of SB202190 (One-way
324 G.F. Pavao-de-Souza et al. / Pharmacology, Biochemistry and Behavior 101 (2012) 320–32830 min before acetic acid (Fig. 4A), PBQ (Fig. 4B) or formalin (Fig. 4C)
stimulus. These dose ranges and vehicle concentration were chosen
based on previous studies (Zhuang et al., 2004; Xu et al., 2007;
Carvalho et al., 2011). Acetic acid (Fig. 4A) and PBQ (Fig. 4B) i.p. injec-
tion induced signiﬁcant nociceptive behavior starting at 6 min. The
doses of 1 and 3 μg of wortmannin did not signiﬁcantly inhibit acetic
acid-induced writhing response (Fig. 4A), and signiﬁcant inhibition
was observed with the dose of 10 μg of wortmannin between
8–20 min compared to vehicle i.t.+acetic acid i.p. group, and be-
tween 16 and 20 min compared to the lower dose of SB202190
(Fig. 4A). The PBQ-induced writhing response was signiﬁcantly re-
duced by 3 μg of wortmannin between 12 and 20 min and by 10 μg
of wortmannin between 10 and 20 compared to vehicle i.t.+PBQ
i.p. group. The dose of 10 μg of wortmannin also signiﬁcantly inhib-
ited PBQ nociception compared to the lower dose of wortmannin
tested between 14 and 20 min (Fig. 4B). The formalin-induced ﬂinch
response was signiﬁcantly reduced by 0.1 μg of wortmannin at 5 min
compared to vehicle i.t.+formalin i.p. group, and by 1 μg of wort-
mannin between 5 and 15 min compared to vehicle i.t.+formalin
i.p. group and the lower dose of wortmannin tested. The dose of
10 μg of wortmannin signiﬁcantly inhibited formalin-induced ﬂinches
in all time points compared to vehicle i.t.+formalin i.p. group and the
lower dose of wortmannin tested (Fig. 4C).
3.5. Combined Treatment with MAP kinases and PI3K inhibitors at doses
that are ineffective as single treatment reduces acetic acid-, PBQ- and
formalin-induced overt pain-like behavior response
Mice received single i.t. treatment with PD98059 (1 μg), SP600125
(1 μg), SB202190 (1 μg) or wortmannin (1 μg), or co-treatment with
1 μg of each MAP kinase inhibitors (PD98059, SP600125, SB202190)
plus 1 μg of wortmannin in a single injection or vehicle (5 μl of 20%
DMSO in saline) 30 min before acetic acid (Fig. 5A) or PBQ (Fig. 5B)
stimulus. In the formalin model mice received single i.t. treatment
with 0.1 μg of each drug or co-treatment in a single injection or vehi-
cle (5 μl of 20% DMSO in saline) 30 min before formalin stimuli
(Fig. 5C). Acetic acid, PBQ and formalin injection nduced signiﬁcant
overtnociceptive response, which was unaffected by single treatment
with PD98059, SP600125, SB202190 or wortmannin (Fig. 5A, B, C andFig. 4. Role of spinal PI3K in acetic acid-, PBQ- and formalin-induced overt pain-like behavio
(20% DMSO in saline) 30 min before acetic acid (Panel A) or PBQ (Panel B) i.p. stimulus and
PBQ 2% DMSO in saline. The cumulative number of writhing responses induced by acetic aci
ber of ﬂinches induced by formalin were determined over 30 min and presented at 5 min in
tative of 2 separated experiments. *Pb0.05 compared with saline; #Pb0.05 compared w
wortmannin (One-way ANOVA followed by Bonferroni's test).D). On the other hand, the combination of those inhibitors at doses
that were ineffective as single treatment signiﬁcantly inhibited acetic
acid-, PBQ- and formalin-induced overt pain-like behavior. This inhi-
bition was also signiﬁcant compared to the all single treatments
(Fig. 5A, B, C and D).
3.6. Role of spinal microglia in acetic acid-, PBQ- and formalin-induced
overt pain-like behavior
Mice received i.t. treatment with microglia inhibitors minocycline
(50 μg—a broad spectrum tetracycline antibiotic, which inhibits
microglia activity) (Maier et al., 2007) or ﬂuorocitrate (1.6 μg—a spe-
ciﬁc inhibitor of microglia Krebs cycle) (Sun et al., 2008) or vehicle
(5 μl of 2% DMSO in saline) 30 min before acetic acid (Fig. 6A), PBQ
(Fig. 6B) or formalin (Fig. 6C) stimulus. These dose ranges and vehicle
concentration were chosen based on previous studies (Milligan et al.,
2003; Ledeboer et al., 2005). Acetic acid, PBQ and formalin injection
induced signiﬁcant overt pain-like behavior response (Fig. 6A, B and
C). The treatment with minocycline and ﬂuorocitrate signiﬁcantly in-
hibit acetic acid-induced writhing response between 10 and 20 min
compared to vehicle i.t.+acetic acid i.p. group (Fig. 6A). The PBQ-
induced writhing response was signiﬁcantly reduced by treatments
between 8 and 20 min (Fig. 6B). The formalin-induced writhing re-
sponse was signiﬁcantly reduced by treatments in all times tested ex-
cept 15 min compared to vehicle i.t.+formalin i.pl. group (Fig. 6C).
4. Discussion
Acetic acid- and phenyl-p-benzoquinone (PBQ)-induced writhing
response are widely used models of overt nociception for screening
and for determination of the mechanism of action of novel drugs. In
the present study, it was demonstrated that acetic acid- and PBQ-
induced writhing response in mice depends on spinal activation of
ERK, JNK, p38 and PI3K, and microglia. Similar results were observed
in the formalin test raising the possibility that the cellular activation
proﬁle in the spinal cord could be similar among these models of
overt pain-like behavior.
Inﬂammatory and neuropathic pain share similar mechanisms in
the spinal cord such as activation of MAP kinases (ERK, JNK andr. Mice received i.t. treatment with wortmannin (1–10 μg or 0.1–10 μg/5 μL) or vehicle
formalin (Panel C) i.pl. stimuli. The vehicle of acetic acid and formalin was saline and
d and PBQ were determined over 20 min and presented at 2 min interval, and the num-
terval. Results are presented as means±s.e.m. of 6 mice per group, and are represen-
ith the acetic acid, PBQ and formalin; **Pb0.05 compared with the lower dose of
Fig. 5. Combined treatment with MAP kinases and PI3K inhibitors at doses that are in-
effective as single treatment reduces acetic acid-, PBQ- and formalin-induced overt
pain-like behavior. Mice received single i.t. treatment with PD98059 (1 μg),
SP600125 (1 μg), SB202190 (1 μg) or wortmannin (1 μg), or co-treatment with 1 μg
of each MAP kinase (PD98059, SP600125, SB202190) and PI3K (wortmannin) inhibi-
tors or vehicle (20% DMSO in saline) 30 min before i.p. injection with acetic acid
(Panel A) or PBQ (Panel B). In the formalin model mice received i.t. treatment with
0.1 μg of each drug, co-treatment with 0.1 μg of each drug in a single injection or vehi-
cle (5 μl of 20% DMSO in saline) 30 min before formalin stimulus (Panel C). The vehicle
of acetic acid and formalin was saline and PBQ 2% DMSO in saline. The results are rep-
resentative of the cumulative writhing responses during 20 min in the acetic acid and
PBQ models, and 0–15 min (ﬁrst phase) and 20–30 min (second phase) in the formalin
model. Results are presented as means±s.e.m. of 6 mice per group, and are represen-
tative of 2 separated experiments. *Pb0.05 compared with saline; #Pb0.05 compared
with acetic acid, PBQ, formalin and single treatments (One-way ANOVA followed by
Bonferroni's test).
325G.F. Pavao-de-Souza et al. / Pharmacology, Biochemistry and Behavior 101 (2012) 320–328p38) and PI3K (Svensson et al., 2003; Ji and Strichartz, 2004; Obata et
al., 2004; Xu et al., 2007; Choi et al., 2010; Fitzsimmons et al., 2010;
Gao and Ji, 2010; Zhang et al., 2011).The activation of spinal MAP ki-
nases and PI3K contribute to hyperalgesia by modulating ion chan-
nels, increasing the production of cytokines and other mediators
and their receptors, and therefore, inducing the sensitization of noci-
ceptors (Ji and Strichartz, 2004; Gao and Ji, 2010). Interestingly, it is
likely that dorsal root ganglia (DRG) and spinal activation of MAP ki-
nases and PI3K also contributes to overt pain-like behavior in the for-
malin test (Pezet et al., 2008; Alter et al., 2010) suggesting that these
kinases might also be involved in the activation of nociceptive neu-
rons and not only in their plasticity and sensitization as demonstrated
in models of inﬂammatory hyperalgesia and chronic neuropathic
pain. In agreement, acute TNFα application rapidly enhances TTX (te-
trodotoxin)-resistant sodium currents in isolated DRG neurons. ThisTNFα enhanced TTX-resistant sodium currents are blocked in TNFR1
(TNF receptor 1) deﬁcient DRG neurons and by p38 inhibitor
(SB202190). Therefore, acute TNFα/TNFR1-induced activation of
p38 MAP kinase can rapidly increase TTX-resistant sodium currents
in DRG neurons resulting in increased neuronal activation (Jin and
Gereau, 2006). Furthermore, the consistent role of MAP kinases and
PI3K in spinal modulation of hyperalgesic and overt pain-like behav-
ior in inﬂammatory and neuropathic pain supports their importance
in nociceptive processes (Svensson et al., 2003; Ji and Strichartz,
2004; Obata et al., 2004; Jin and Gereau, 2006; Xu et al., 2007; Pezet
et al., 2008; Choi et al., 2010; Fitzsimmons et al., 2010; Alter et al.,
2010; Carvalho et al., 2011; Zhang et al., 2011).
Moreover, in the formalin test PI3K inhibition diminishes the noci-
ceptive behavior in both phases by mechanisms involving reduced
ERK and CaMKII (calcium–calmodulin-dependent protein kinase II)
phosphorylation, decreases the phosphorylation of the NMDA recep-
tor subunit NR2B, decreases translocation to the plasma membrane of
the GluR1 (glutamate receptor 1) AMPA receptor subunit in the spi-
nal cord as well as reduces evoked neuronal activity as measured
using c-Fos immunohistochemistry (Pezet et al., 2008). This activa-
tion of spinal PI3K by peripheral formalin injection activates the
PI3K/Akt/mTOR (mammalian target of rapamicyn) signaling pathway
in the spinal cord contributing to neuronal excitability. Co-
localization studies using immunoﬂuorescence indicated that forma-
lin activates the PI3K/Akt/mTOR signaling pathway in neurons (Xu
et al., 2011). The ERK activation in the formalin test was reported to
be relevant in both phases of formalin test similar to the PI3K inhibitor
results and present data (Pezet et al., 2008; Alter et al., 2010; Xu et al.,
2011 and present data), which is consistent with the PI3K-dependent
activation of ERK in the formalin test (Pezet et al., 2008). However, it
remains to be shown in which cell or cells ERK is being activated by
peripheral formalin stimulus. Nevertheless, it is likely that this ERK
activation occurs in the same cell as PI3K as shown in other models
(Zhuang et al., 2004; Guan et al., 2010).
JNK inhibitors were reported to inhibit the second phase of forma-
lin test (Li et al., 2010a, 2010b, 2010c) and herein it was detected its
participation in both phases. It is possible that the difference between
strains (Swiss mice versus many mice strains tested except the Swiss
strain) and doses of formalin (25 μl of 1.5% formalin versus 20 μl of 5%
formalin) might explain these divergent data (present data and Li et
al., 2010a, 2010b, 2010c, respectively).
On the other hand, regarding p38, the present results indicate its
role in both phases of formalin test as previously described (Hua et
al., 2005). The evidence in the formalin model indicates that p38 is ac-
tivated in microglia cells since it was inhibited by minocyclin (a broad
spectrum tetracycline antibiotic, which inhibits microglia activity—
Maier et al., 2007) treatment (Li et al., 2010a, 2010b, 2010c). Further-
more, other nociceptive stimuli such as substance P and carrageenin
induce p38 activation in spinal microglia (Li et al., 2010a, 2010b,
2010c). In the present study it was observed that minocyclin and
ﬂuocitrate (a speciﬁc inhibitor of microglia Krebs cycle—Sun et al.,
2008) diminished formalin-, acetic acid- and PBQ-induced overt
pain-like behavior suggesting the role of spinal microglia in these re-
sponses. Furthermore, p38 can also be activated in astrocytes (Sorkin
et al., 2009) as well as low levels of p38 phosphorylation were
detected in astrocytes and neurons (Li et al., 2010a, 2010b, 2010c).
Although there are many studies on the spinal kinases activated
by peripheral injection of formalin in the paw, there is only a partial
picture of the mechanisms activated in each cell in the spinal cord
or DRG in this model, which was constructed in association with
data in the carrageenin- and complete Freund's adjuvant-induced
paw inﬂammation and intrathecal administration of substance P
(Svensson et al., 2003; Hua et al., 2005; Alter et al., 2010; Xu et al.,
2011). At the moment, it can be concluded that after formalin injec-
tion there is PI3K activation in the spinal cord neurons, which seems
to be an initial step and is responsible for ERK activation, possibly in
Fig. 6. Role of spinal microglia in acetic acid-, PBQ- and formalin-induced overt pain-like behavior. Mice received single i.t. treatment with minocycline (50 μg), ﬂuorocitrate (1.6 μg)
or vehicle (5 μl of 2% DMSO in saline) 30 min before acetic acid (Fig. 6A), PBQ (Fig. 6B) or formalin (Fig. 6C) stimulus. The vehicle of acetic acid and formalin was saline and PBQ 2%
DMSO in saline. The cumulative number of writhing responses induced by acetic acid and PBQ were determined over 20 min and presented at 2 min interval, and the number of
ﬂinches induced by formalin were determined over 30 min and presented at 5 min interval. Results are presented as means±s.e.m. of 6 mice per group, and are representative of 2
separated experiments. *Pb0.05 compared with saline; #Pb0.05 compared with acetic acid, PBQ and formalin (One-way ANOVA followed by Bonferroni's test).
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Guan et al., 2010; Xu et al., 2011). It is unclear in which cell in the spi-
nal cord JNK is activated after formalin injection in the paw while p38
activation occurs mainly in microglia though its activation is also
detected, to a lesser extent, in astrocytes and neurons (Sorkin et al.,
2009; Li et al., 2010a, 2010b, 2010c). Taking into account the similar
pharmacological susceptibility with kinase and microglia inhibitors
in the formalin (Watkins et al., 1997; Hua et al., 2005; Qin et al.,
2006; Lan et al., 2006; Sorkin et al., 2009; Li et al., 2010a, 2010b,
2010c; Pezet et al., 2008; Alter et al., 2010; Xu et al., 2011, present
data), acetic acid and PBQ models (present data), it is possible that
these peripheral stimuli (e.g. formalin, acetic acid and PBQ) induce
ﬂinch and writhing responses by activating similar spinal mecha-
nisms including cells and kinases, which merit further investigation.
Corroborating, in a model of visceral pain induced by the intrarectal
administration of formalin, there is spinal activation of p38 and c-
Fos expression (Xu et al., 2010). Thus, visceral administration of for-
malin can activate similar spinal mechanisms as formalin injection
in the paw as well as acetic acid or PBQ intraperitoneal administration
seem to activate similar mechanisms to formalin injected in the paw
or intrarectal.
Importantly, we have previously shown that none of the intrathe-
cal treatments with kinase inhibitors tested herein alters mechanical
hyperalgesia in the contra-lateral paw to G-CSF (granulocyte-colony
stimulating factor) stimulus, indicating that PD98059, SB600125,
SB202190 and wortmannin do not alter the basal mechanical thresh-
old of normal tissue (Carvalho et al., 2011). Thus, it is unlikely that
these inhibitors would affect the basal visceral response at the doses
tested. TheMAP kinase and/or PI3K inhibitors andmicroglia inhibitors
(minocycline and ﬂuorocitrate) used herein reduced by up to 60% and
35% the acetic acid- and up to 80% and 48% the PBQ-induced writhing
response, respectively. It is possible that higher doses of inhibitors
could result in abolishment of nociception, however, we refrain to
use doses that are higher than those in the literature to avoid losing
their selectivity (Watkins et al., 1997; Milligan et al., 2003; Zhuang
et al., 2004, 2005; Ledeboer et al., 2005; Hua et al., 2005; Doya et al.,
2005; Qin et al., 2006; Lan et al., 2006; Xu et al., 2007; Chen et al.,
2009). The result demonstrating that the combined treatment, at
doses that are ineffective as single treatment, abolished acetic acid-
and PBQ-induced writhing and formalin-induced ﬂinch responsesuggests a sequential and/or synergic role of spinal p38, ERK, JNK,
and PI3K in these nociceptive responses. Corroborating a sequential
pathway and the interaction of PI3K and MAP kinases, PI3K activates
ERK in primary sensory neurons inducing heat andmechanical hyper-
algesia (Zhuang et al., 2004; Guan et al., 2010) and in the spinal cord
mediating formalin nociception (Pezet et al., 2008). MAP kinases pre-
sent a different interaction among them compared to PI3K/MAP ki-
nases relationship since they can act in a co-dependent manner to
activate transcription factors such as activating protein-1 (AP-1) as
known for JNK and ERK (Kim and Iwao, 2003). On the other hand,
p38, ERK and JNK, in general, do not activate each other. Corroborat-
ing, ERK and p38 inhibitors do not affect G-CSF-induced JNK activa-
tion in a model of cell proliferation (Rausch and Marshall, 1997).
Thus, the combined treatment with MAP kinases and PI3K inhibitors
could allow reduced doses of such inhibitors (1 μg of each inhibitor
in the writing tests or 0.1 μg of each inhibitor in the formalin test)
compared to single drug treatment (10 μg of a single inhibitor).
Peripheral administration of cytokines such as G-CSF and other in-
ﬂammatory mediators induces mechanical hyperalgesia dependent
on spinal MAP kinases and PI3K (Carvalho et al., 2011; Guan et al.,
2010). Therefore, it is conceivable that peripheral nociceptive media-
tors produced in response to acetic acid, PBQ and formalin would be
responsible for spinal activation of ERK, JNK, p38 and PI3K. In agree-
ment, cytokines such as TNFα and IL-1β which mediate acetic acid
writhing response (Ribeiro et al., 2000) and second phase of formalin
test (Chichorro et al., 2004) induce neuronal and non-neuronal acti-
vation of ERK, JNK, p38 and/or PI3K (Ji and Strichartz, 2004; Sung et
al., 2005; Davis et al., 2006; Takada et al., 2008; Zhang et al., 2011).
The PBQ stimulus trigger a different peripheral cytokine cascade com-
pared to acetic acid, it induces writhing response dependent on IL-18,
IFNγ and endothelin-1 (Verri et al., 2008b). These mediators also in-
duce ERK, JNK, p38 and/or PI3K activation in neuronal and non-
neuronal cells (Miyoshi et al., 2008; Seo et al., 2009; Kim et al.,
2010; Oyeniran and Tanﬁn, 2011). Initially, two models of writing re-
sponse were used to investigate whether the difference in peripheral
mediators would result in different spinal mechanisms, and the for-
malin test was used because it present some similarities regarding
peripheral mediators compared to acetic acid (Ribeiro et al., 2000;
Chichorro et al., 2004) and for comparison purposes with previous
spinal mechanisms demonstrated in formalin test. However, although
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each model (acetic acid, PBQ and formalin) and the observed behav-
ior (writhing and ﬂinch), the consistent spinal similarities regarding
the role of microglia, ERK, JNK, p38 and PI3K suggests a common spi-
nal integrative pathway between peripheral and central processing of
pain in these models. These mechanisms are also consistent in models
of hyperalgesia induced by carrageenan, complete Freund's adjuvant
and substance P (Svensson et al., 2003; Pezet et al., 2008; Alter et
al., 2010; Xu et al., 2011). Therefore, demonstrating the importance
of these signaling pathways in nociceptive responses and suggesting
them as therapeutic targets.
The present study demonstrated, to our knowledge, the ﬁrst evi-
dence that spinal MAP kinases (ERK, JNK and p38) and PI3K, and
microglia mediate acetic acid- and PBQ-induced writhing response
in mice. It is also important to note the increase effectiveness of co-
treatment with kinases inhibitors compared to single kinase inhibitor
at ineffective doses to reduce acetic acid, PBQ and formalin overt
pain-like behaviors. These results suggest that these fast learning/
performing and low cost models of nociception could also be used
to evaluate the activity of MAP kinases, PI3K and microglia inhibitors
as well as that these mechanisms may also be involved in the action
of novel drugs tested in these models. Nevertheless, further co-
localization studies and biochemical evidence is necessary to consol-
idate the present behavioral and pharmacological data.
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